Blog Archive
-
▼
2010
(70)
-
▼
June
(15)
- Sanofi-aventis and Metabolex : Exclusive Worldwide...
- MannKind : Study Showing AFREZZA(TM) Provides Comp...
- Diamyd Medical and Ortho-McNeil-Janssen Pharmaceut...
- Metabolex and Ortho-McNeil-Janssen Pharmaceuticals...
- Lexicon Pharmaceuticals : Data Describing LX4211 P...
- Avid Radiopharmaceuticals : Clinical Trial Advance...
- Wright Medical Group : Commercial Launch of the VA...
- Home Diagnostics and Nipro Diabetes Systems : Plan...
- Cyntellect And Boston University To Collaborate In...
- Zydus Cadila : novel orally administered GLP-1 ago...
- Omni Bio Pharmaceutical : FDA IND Clearance for Al...
- LifeScan Canada collaborates with country's first ...
- Forest Laboratories and TransTech Pharma : License...
- OrbusNeich : Effectiveness of OrbusNeich's Genous™...
- GENFIT : Two major pre-diabetes clinical trials wi...
-
▼
June
(15)
Monday, June 21, 2010
Cyntellect And Boston University To Collaborate In Diabetes And Anemia Research
DECEMBER 2, 2009 — Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced it has entered into a research collaboration agreement with the Boston University School of Medicine. The agreement focuses on advancing research in the roles of mitochondrial oxidative damage in degenerative, aging and metabolic diseases, such as anemia and diabetes. Boston University scientists will use Cyntellect’s award-winning LEAP™ Cell Processing Workstation to analyze, purify and process cells with great precision and simplicity within microplates, right where they are grown in the lab... [PDF] Cyntellect's Press Release -